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Abstract
Objectives:  To  improve  glycemic  control  and  prevent  late 
complications, the patient and diabetes team need to adjust insulin 
therapy. The aim of this study is to evaluate the efficacy of thrice-
daily versus twice-daily insulin regimens on HbA1c for type 1 
diabetes mellitus by a randomized controlled trial in Hamedan, 
west of Iran.
Methods:  The  study  included  125  patients  under  19  years  of 
age with type 1 diabetes mellitus over a 3- month period. All 
patients  with  glycohemoglobin  (HbA1c)  ≥8%  were  followed 
prospectively and randomized into two trial and control groups. 
The control group received conventional two insulin injections per 
day: a mixture of short-acting (regular) + intermediated acting 
(NPH) insulins pre-breakfast (twice daily), and the trial group 
was treated by an extra dose of regular insulin before lunch (three 
times daily). Main outcome measure was HbA1c at baseline and 
at the end of 3 months. The mean blood glucose level and number 
of hypoglycemia were recorded. All patients underwent monthly 
intervals follow up for assessing their home blood glucose records 
and insulin adjustment.
Results: Overall, 100 patients completed the study protocol. 52% 
were females, mean ± SD of age of 12.91 ± 3.9 years. There were 
no significant differences in baseline characteristics including age, 
gender, pubertal stage, adherence to diet, duration of disease and 
total daily insulin dose (p>0.05). There was a significant decrease 
individually in both groups in HbA1c level (p<0.05), but there was 
no significant difference in HbA1c reduction in patients on twice-
daily insulin injections and those on thrice-daily insulin injection 
groups (1.12 ± 2.12 and 0.98 ± 2.1% respectively, p>0.05).
Conclusion:  Compared  with  twice  daily  insulin,  a  therapeutic 
regimen involving the addition of one dose regular insulin before 
lunch caused no significant change in the overall glycemic control of 
patients with type 1 diabetes mellitus. Our results emphasize that 
further efforts for near normoglycemia should be focused upon 
education of patients in terms of frequent outpatient visits, more 
blood glucose monitoring and attention to insulin adjustments
Introduction
The  optimal  glycemic  control  is  a  key  component  in  the 
treatment  of  diabetes  mellitus.  Long  term  studies  indicate 
that  good  metabolic  control  delays  the  onset  and  slows  down 
the  progression  of  microvascular  complications.1  Diabetes 
Control and Complications Trial (DCCT) confirmed that near 
normal glycohemoglobin (HbA1c) prevents the development of 
complications or delays their progressions.2
Recommendations therefore issue that youths with diabetes 
should be treated with intensive therapy to normalize glycemic 
control as early as possible.3 Achieving optimal glycemic control 
is especially challenging in patients with type 1 diabetes mellitus 
(T1DM).  Intensive  therapy  involves  multiple  daily  injections 
of  insulin  or  insulin  pump  therapy,  as  well  as  other  essential 
components of diabetes care, such as self- monitoring of blood 
glucose.4,5 In multiple daily insulin injection regimens, the use 
of  rapid  acting  analogs,  rather  than  regular  insulin  therapy  is 
associated with improvements in both postprandial glycemia and 
HbA1c concentration.6,7 On the other hand, treatment costs with 
rapid acting analogs are expensive and sometimes they are also not 
available. For these reasons, diabetic children sometimes may need 
an extra dosage of regular insulin before lunch for intensifying 
treatment. To recommend this, clarity is needed with respect to 
the effects of adding a dose of insulin before lunch treatment. To 
that aim, we systematically reviewed the accessible impact on the 
effects of extra dosage of insulin before lunch on blood glucose 
control. By our knowledge, limited researchers have investigated 
the effect of three times daily insulin dose versus twice regimens on 
HbA1c on type 1 diabetic recently.8 Therefore, in this prospective 
randomized controlled trial, we investigate whether the addition of 
insulin regular pre-lunch is superior to that of a conventional two-
injection therapy on glycemic control of type 1 diabetic patients.
Methods
This  prospective  randomized  clinical  trail  was  conducted  in 
Ekbatan  Hospital,  Hamedan  University  of  Medical  Sciences 
of Iran in 2004. The primary efficacy endpoint was to compare 
the change in HbA1c from baseline to endpoint (3months). The 
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major inclusion criteria were; type 1 diabetic patients ≤19 yrs with 
duration of diabetes for at least 1 year and baseline HbA1c ³ 8% 
who were being followed at the diabetes outpatient clinic. To be 
included in the study, subjects were also required to have blood 
glucose meter for self monitoring of their blood glucose.
Patients  were  excluded  if  they  were  taking  any  other 
medication, had other diseases, refused treatment or failed for 
follow-up. In terms of ethical considerations; patients and their 
parents gave their informed consent and the protocol was approved 
by the local ethics committee and research of Hamedan University 
of Medical Sciences, in 2004. All diabetic patients were already on 
conventional insulin regimen and receiving two insulin injections 
per day. In this plan, two thirds of the daily total dose was given 
before breakfast and one third was given before evening meal. 
Each injection consisted of intermediate and short acting insulins 
(NPH and Regular respectively) in proportions of 2:1. At the 
onset of diabetes, the total daily insulin varies from 0.5-1.0 Unit/
kg. Adjustments in the dose of insulin are made in relation to the 
pattern of blood glucose values monitored before each meal.
A total of 125 patients withT1DM were enrolled in the study. 
At entry into the study; mean age, gender, diabetes duration and 
total daily insulin dose in both groups were comparable. The yearly 
frequency visits of the studied patients was 3.8 ± 2.0 times. Diet, 
physical activity, correct injection in different sites were similar 
before and after the study.
The patients were trained properly for frequent contact and 
more  home  blood  glucose  monitoring.  The  primary  endpoint 
of our study was HbA1C. Subjects were randomly divided into 
two groups; trial and control groups. The control group received 
conventional insulin regimen: a mixture of short-acting (regular) 
+ intermediate (NPH) insulins pre-breakfast and before evening 
meal (twice daily), and the trial group was treated by three daily 
injections  regimen:  mixture  of  regular  +  NPH  insulins  pre-
breakfast,  an  extra  dose  of  0.2  Unit/kg  regular  insulin  before 
lunch and mixture of regular + NPH insulin before supper (three 
times daily).
All patients were seen at monthly intervals during the study 
for evaluation of their blood glucose records. HbAlc was measured 
at baseline and at the end of the study. HbA1c was measured using 
the DCA
2000 Analyzer (Bayer, Tarrytown, NY). Meanwhile, the mean 
of  self-monitoring  and  monthly  serum  glucose,  hypoglycemic 
attack and occurrence of diabetic ketoacidosis were recorded. The 
data was manually extracted and displayed in a descriptive manner.
Statistical analysis: Chi square test and t- test or paired t test 
were used for non-parametric and parametric variables respectively 
using SPSS 11 software. A p-value less than 0.05 was defined as 
statistically significant.
Results
A  total  100/125  subjects  completed  the  study  protocol.  Nine 
patients  from  the  control  group  and  16  of  the  study  group 
refused the allocated regimen and dropped out of the study. 50 
patients  were  randomly  assigned  to  trial  (Thrice-daily  insulin 
injection)  and  50  were  enrolled  into  the  control  group  (twice-
daily insulin injections). The clinical characteristics of each group 
are summarized in Table 1. HbA1c values were similar in both 
study groups at baseline. Meanwhile the total daily insulin intake 
increased similarly in both the trial and the control groups.
In both groups, the mean HAb1c decreased significantly after 
three months (p<0.05) but the reduction of HbA1c at the end of 3 
months was not different between the two insulin regimens (1.12 
± 2.12 and 0.98 ± 2.1% respectively), (p>0.05). (Table 2)
The mean blood glucose levels after the study were 241.5 ± 
78.8 mg/dL and 211.3 ± 49.4 mg/dL in control and trial groups 
respectively, (p=0.14), the difference was not significant (p>0.05). 
Hypoglycemic (defined as blood glucose <45mg/dL) occurred in 
10% of the patients in both groups, but the difference was not 
significant, (p>0.05). (Table 1).
Table 1: Patients’ Characteristics of Control and Trail groups 
Parameter
Daily insulin Regimen
Twice-daily Thrice-daily p value
Sex
female 24 (48%) 28 (56%)
*p=0.42
male 26 (52%) 22 (44%)
Age (year) 11.9 ± 4.3 14.3 ± 3 **p=0.056
Duration  of  diabetes 
mellitus(year)
2.97 ± 2.9 4.7 ± 3.3 **p=0.72
Blood  glucose  after 
treatment (mg/dL)
241.5 ± 78.8 211.3 ± 49.4 **p=0.14
Hypoglycemia 4 (8%) 6 (12%) p=0.34
* Chi-square,**t-test
Control group (n=46) and Trail group (n=46)
Data presented as No.(%) or mean ±SD where appropriate.
Table 2: Comparisons of the HbA1c of the control and trial groups
HbA1c (%)
Daily insulin regimen
Twice-daily Thrice-daily * p value
Baseline 11.21 ± 2.46 10.64 ± 1.66 p=0.032
After study 10.23 ± 2.47 9.51 ± 1.94 p=0.043
Decrease in HbA1c 0.98 ± 2.1 1.12 ± 2.12 p=0.82
**t-test
Data is presented as mean ±SD
Discussion
HbA1C has been recognized as the gold standard for monitoring 
blood glucose control.9 The most widely recommended strategy 
for treating of T1 DM patients is conventional insulin regimen 
twice daily; a mixture of short-acting (regular) + intermediate 
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(NPH) insulins pre-breakfast and pre supper in the region of Iran.
The main purpose of this study was to investigate the efficacy 
of three-times daily insulin regimen on mean HbA1c of type 1 
diabetic children and adolescents. This was done by comparing 
twice daily versus three times daily insulin regimen on patients 
who participated in the study.
The primary analysis showed that in this group of patients, 
improved metabolic control was not achieved with three times 
daily  insulin  regimen.  This  can  probably  be  explained  by  the 
fact that the starting HbA1c was lower in thrice-daily injections 
than twice-daily injection group. In some previous studies, other 
authors have also reported similar results. Hinde and Johnston 
demonstrated that three injections of insulin caused no significant 
reductions in HbAlc level in adolescence.8 Also, Dorchy et al. 
reported that in comparison with the two daily insulin in children, 
four injections did not significantly reduce the mean HbA1c of 
adolescents.10 Mortensen et al. during a 2-year period were faced 
with deterioration in metabolic control of diabetic patients despite 
the  use  of  multiple  injection  regimens.  They  claimed  that  the 
possible reasons for deterioration of HbA1c could be attributed to 
the increased body mass index in all the study groups.11 In a cross-
sectional study involving 22 pediatric departments, Mortensen et 
al. concluded that in spite of tendency towards intensive attention, 
the goal of near normoglycemia was achieved in only a few.12 Some 
studies have failed to support our findings. Bougnères et al. showed 
improved metabolic control in adolescents with T1DM who had 
previously failed to respond to two insulin injections a day.13
An important finding of the current study is that the similar 
reductions in HbA1c occurred in both the trial and the control 
group at the study endpoint. Since, the studied patients were asked 
to perform in average, four times blood glucose measurements 
per week and were asked to keep in contact for insulin dosage 
adjustment  between  monthly  interval  visits,  and  all  did  so 
therefore,  the  reduction  of  HbA1c  could  be  attributed  to  the 
intensive  medical  attention  including  frequent  contact,  more 
outpatient visits and increased frequency of home blood glucose 
monitoring. This highlights the need for intensive education of 
the patients and their families. Some reports have shown that 
increased frequency of home blood glucose monitoring, results in 
significant improvements in glycemic control.10,14,15 This finding is 
in contrast to the results by Worth et al. who reported that home 
blood glucose monitoring did not lead to a significant improvement 
in glycemic control of 46 diabetic patients.16
Hypoglycemia is a frequent and sometimes dangerous acute 
complication of T1DM. There were no differences encountered 
in rates of hypoglycemia between the control and trial groups. 
Similar findings were reported by other workers.17
The study limitations include the fact that the study was not 
double blinded according to the procedure. Also, the duration of 
the study was short coupled with a small sample size of subjects. 
Thus further research should be conducted with larger sample size 
and longer follow up periods. In addition, the result of this modest 
intensification in insulin treatment was not sufficiently powered 
to  be  extrapolated  to  the  general  clinical  setting.  Therefore,  it 
warrants compaction with results of previously reported findings.
Conclusion
The overall glycemic control in patients using three-times daily 
insulin  regimen  was  similar  with  conventional  two-injection 
therapy. Twice-daily insulin administration is the most simple and 
cost- effective regimen. Our study suggests that frequent follow 
up, regular outpatient visits, more blood glucose monitoring and 
attention to insulin adjustment are fundamentally important for 
improving glycemic control. Overall, glycemic control, frequency 
of hypoglycemic events, and total insulin dose were not different 
between the two groups.
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